Positron Emission Tomography/Computed Tomography with Gallium-68-labeled Prostate-specific Membrane Antigen Detects Relapse After Vascular-targeted Photodynamic Therapy in a Prostate Cancer Model.

[1]  Hossein Jadvar,et al.  PSMA Theranostics: Current Status and Future Directions , 2018, Molecular imaging.

[2]  A. Scherz,et al.  Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts , 2018, Clinical Cancer Research.

[3]  K. Rahbar,et al.  Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid , 2018, Oncotarget.

[4]  M. Schwaiger,et al.  Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  R. Mach,et al.  Consensus nomenclature rules for radiopharmaceutical chemistry - Setting the record straight. , 2017, Nuclear medicine and biology.

[6]  H. Lepor,et al.  Multi-parametric MRI imaging of the prostate—implications for focal therapy , 2017, Translational andrology and urology.

[7]  P. Rosenberg,et al.  Trends in the Incidence of Fatal Prostate Cancer in the United States by Race. , 2017, European urology.

[8]  Antonio Alcaraz,et al.  Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. , 2017, The Lancet. Oncology.

[9]  Peter Bankhead,et al.  QuPath: Open source software for digital pathology image analysis , 2017, Scientific Reports.

[10]  M. Dziuk,et al.  68Ga-PSMA PET/CT imaging in recurrent prostate cancer: Where are we now? , 2017, Central European journal of urology.

[11]  Damien Bolton,et al.  Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. , 2016, European urology.

[12]  A. Oto,et al.  Magnetic Resonance Imaging of the Prostate, Including Pre- and Postinterventions , 2016, Seminars in Interventional Radiology.

[13]  M. Schwaiger,et al.  68Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report , 2016, Cancer Imaging.

[14]  P. Scardino,et al.  Nonthermal Ablation by Using Intravascular Oxygen Radical Generation with WST11: Dynamic Tissue Effects and Implications for Focal Therapy. , 2016, Radiology.

[15]  W. Lowrance,et al.  Recent decline in prostate cancer incidence in the United States, by age, stage, and Gleason score , 2015, Cancer medicine.

[16]  W. Horninger,et al.  68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  S. Taneja,et al.  Focal therapy for prostate cancer: The current status , 2015, Prostate international.

[18]  A. Scherz,et al.  TOOKAD® Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer , 2015, World Journal of Urology.

[19]  Andriy Fedorov,et al.  The Role of Pathology Correlation Approach in Prostate Cancer Index Lesion Detection and Quantitative Analysis with Multiparametric MRI , 2015, Academic radiology.

[20]  Nathan Lawrentschuk,et al.  The Role of Focal Therapy in the Management of Localised Prostate Cancer: A Systematic Review , 2014, European urology.

[21]  Hessel Wijkstra,et al.  The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel , 2014, BJU international.

[22]  Jiaoti Huang,et al.  The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. , 2012, Cell stem cell.

[23]  Vyacheslav Kalchenko,et al.  Permanent Occlusion of Feeding Arteries and Draining Veins in Solid Mouse Tumors by Vascular Targeted Photodynamic Therapy (VTP) with Tookad , 2010, PloS one.

[24]  岸本 武利,et al.  PSMA(prostate-specific membrane antigen)をターゲットにした前立腺癌の免疫療法の試み , 2002 .